STAT1 Is Required for Decreasing Accumulation of Granulocytic Cells via IL-17 during Initial Steps of Colitis-Associated Cancer
Open accessThe DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.
Abstract
Signal transducer and activator of transcription 1 (STAT1) acts as a tumor suppressor molecule in colitis-associated colorectal cancer (CAC), particularly during the very early stages, modulating immune responses and controlling mechanisms such as apoptosis and cell proliferation. Previously, using an experimental model of CAC, we reported increased intestinal cell proliferation and faster tumor development, which were consistent with more signs of disease and damage, and reduced survival in STAT1-/- mice, compared with WT counterparts. However, the mechanisms through which STAT1 might prevent colorectal cancer progression preceded by chronic inflammation are still unclear. Here, we demonstrate that increased tumorigenicity related to STAT1 deficiency could be suppressed by IL-17 neutralization. The blockade of IL-17 in STAT1-/- mice reduced the accumulation of CD11b+Ly6ClowLy6G+ cells resembling granulocytic myeloid-derived suppressor cells (MDSCs) in both spleen and circulation. Additionally, IL-17 blockade reduced the recruitment of neutrophils into intestinal tissue, the expression and production of inflammatory cytokines, and the expression of intestinal STAT3. In addition, the anti-IL-17 treatment also reduced the expression of Arginase-1 and inducible nitric oxide synthase (iNOS) in the colon, both associated with the main suppressive activity of MDSCs. Thus, a lack of STAT1 signaling induces a significant change in the colonic microenvironment that supports inflammation and tumor formation. Anti-IL-17 treatment throughout the initial stages of CAC related to STAT1 deficiency abrogates the tumor formation possibly caused by myeloid cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of IL-17 reduced the recruitment of G-MDSC into intestinal specimen of STAT1 -/- mice and significantly decreased the expression of ARG1 and inducible nitric oxide synthase (iNOS) [317].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [317]
In the citing paper
“Preclinical studies have demonstrated that STAT1 recruits G-MDSC through IL-17 in colitis-associated colorectal cancer (CAC) models.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [317]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Interleukin‑17 promotes the development of cisplatin resistance in colorectal cancer
Sui, G., Qiu, Y., Yu, H., Kong, Q., & Zhen, B. (2018) · Oncology Letters · doi:10.3892/ol.2018.9645 · Cited by 53 · cited 1×
“IL-17 levels are increased in tumor tissues and in the sera of colon cancer patients [12,13], and a high expression of IL-17 in tumor regions has been proposed as an indicator of prognosis in patients with colorectal carcinoma [14].”
BackgroundRetractedMyeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812 · cited 1×
“Antibody-mediated IL-17A neutralization blocked ETBF-induced colitis and tumorigenesis [44].”
BackgroundRodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276 · cited 2×
“Arginase-1 and iNOS activity promote tumor growth that escapes from immune surveillance through the depletion of L-arginine [26]; thus, we analyzed the levels of iNOS and Arginase-1 (Arg-1) expression in the intestine as a result of the activation of MDSCs in a pathological context.”
BackgroundTosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146 · cited 1×
“An in situ analysis of the density of IL-17+ cells in human colorectal cancer specimens showed that a high “Th17 signature” confers severely reduced disease-free survival after the resection of primary tumors [45].”
BackgroundIL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842 · cited 1×
“IL-17 induces the production of IL-6 by stromal and tumor cells, thus activating the STAT3 pathway, which favors the expression of inflammatory factors important for the regulation of leukocyte infiltration in inflammatory tissues [20].”
BackgroundTumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792 · cited 1×
“Several studies have linked the activation of STAT1 with MDSCs’ suppressive activity [36,37].”
BackgroundWu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445 · cited 1×
“Several studies have linked the activation of STAT1 with MDSCs’ suppressive activity [36,37].”
BackgroundCorvinus, F. M., Orth, C., Moriggl, R., Tsareva, S. A., Wagner, S., Pfitzner, E. B., Baus, D., Kaufman, R., Huber, L. A., Zatloukal, K., et al. (2005) · Neoplasia · doi:10.1593/neo.04571 · Cited by 427 · cited 1×
“The increased activity of STAT3 is common in colon cancer, and STAT3 phosphorylation has been related to tumor cell survival and proliferation, and tumor angiogenesis [27].”
BackgroundLiu, J., Duan, Y., Cheng, X., Chen, X., Xie, W., Long, H., Lin, Z., & Zhu, B. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.021 · Cited by 361 · cited 1×
“IL-17 levels are increased in tumor tissues and in the sera of colon cancer patients [12,13], and a high expression of IL-17 in tumor regions has been proposed as an indicator of prognosis in patients with colorectal carcinoma [14].”
BackgroundWang, K., Kim, M. K., Di Caro, G., Wong, J., Shalapour, S., Wan, J., Zhang, W., Zhong, Z., Sanchez-Lopez, E., Wu, L.-W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.11.009 · Cited by 341 · cited 1×
“IL-17A neutralization restores responsiveness to chemotherapy in colon cancer and resensitizes cells to cytotoxic treatments [46].”
BackgroundHe, D., Li, H., Yusuf, N., Elmets, C. A., Li, J., Mountz, J. D., & Xu, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902574 · Cited by 334
Xu, X., Fu, X.-Y., PLATE, J. M. D., & Chong, A. S. (1998) · PubMed · Cited by 283
STAT1 as a key modulator of cell death
Kim, H. S., & Lee, M.-S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.09.003 · Cited by 279 · cited 1×
“This is related to the ability of STAT1 to induce the expression of members of the cell surface death receptor family and their ligands [9,10] and a number of proapoptotic and cell-cycle genes, such as caspases, BCL-2, BCL-XL, p27, and p21WAF1 [11].”
BackgroundIL-17A Produced by γδ T Cells Promotes Tumor Growth in Hepatocellular Carcinoma
Ma, S., Cheng, Q., Cai, Y., Gong, H., Wu, Y., Yu, X., Shi, L., Wu, D., Dong, C., & Liu, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2534 · Cited by 264
The good and the bad faces of STAT1 in solid tumours
Meissl, K., Macho-Maschler, S., Müller, M., & Strobl, B. (2017) · Cytokine · doi:10.1016/j.cyto.2015.11.011 · Cited by 264 · cited 3×
“Many lines of evidence suggest that STAT1 acts as a tumor suppressor molecule in various malignancies [1,2], prompting antiproliferative and proapoptotic responses and enhancing antitumor immunity [2].”
BackgroundSTAT3 in Cancer—Friend or Foe?
Zhang, H.-F., & Lai, R. (2014) · Cancers · doi:10.3390/cancers6031408 · Cited by 219
JAK/STAT/SOCS‐signaling pathway and colon and rectal cancer
Slattery, M. L., Lundgreen, A., Kadlubar, S. A., Bondurant, K. L., & Wolff, R. K. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.21841 · Cited by 192
Jess, T., Winther, K. V., Munkholm, P., Langholz, E., & Binder, V. (2002) · Gastroenterology · doi:10.1053/gast.2002.33632 · Cited by 191
Neufert, C., Becker, C., Wirtz, S., Fantini, M. C., Weigmann, B., Galle, P. R., & Neurath, M. F. (2007) · European Journal of Immunology · doi:10.1002/eji.200636896 · Cited by 190 · cited 1×
“On the contrary, STAT1 is recognized as an inhibitor of the Th17 differentiation pathway, and Th17 responses are affected by STAT1-activating cytokines such as IFN-γ and IL-27 [21].”
BackgroundRole of IL-17A in the development of colitis-associated cancer
Hyun, Y. S., Han, D. S., Lee, A. R., Eun, C. S., Youn, J., & Kim, H.-Y. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs106 · Cited by 182 · cited 2×
“The inflammation and proliferation scores of IL-17A-deficient mice were significantly lower than those of WT mice in the AOM-DSS model of CAC [42].”
BackgroundSimpson, J. A. D., Al-Attar, A., Watson, N. F. S., Scholefield, J. H., Ilyas, M., & Durrant, L. G. (2010) · Gut · doi:10.1136/gut.2009.194472 · Cited by 167 · cited 1×
“tive correlation of STAT1 expression and better prognosis [4,5].”
BackgroundIL-17 and colorectal cancer: From carcinogenesis to treatment
Razi, S., Noveiry, B. B., Keshavarz‐Fathi, M., & Rezaei, N. (2019) · Cytokine · doi:10.1016/j.cyto.2018.12.021 · Cited by 150 · cited 3×
“IL-17 levels are increased in tumor tissues and in the sera of colon cancer patients [12,13], and a high expression of IL-17 in tumor regions has been proposed as an indicator of prognosis in patients with colorectal carcinoma [14].”
BackgroundInterleukin-17: A Promoter in Colorectal Cancer Progression
Wu, D., Wu, P., Huang, Q., Liu, Y., Ye, J., & Huang, J. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/436307 · Cited by 124 · cited 1×
“Different experimental studies have demonstrated that elevated IL-17 expression promotes colon cancer development [13,42,43].”
BackgroundMyeloid-Derived Suppressor Cells: Ductile Targets in Disease
Consonni, F. M., Porta, C., Marino, A., Pandolfo, C., Mola, S., Bleve, A., & Sica, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00949 · Cited by 116 · cited 1×
“Suppressive M-MDSCs are characterized by the expression of iNOS and the production of nitric oxide (NO), while PMN-MDSCs produce reactive oxygen species (ROS) and arginase 1 (Arg1) as part of their immunosuppressive phenotype [47].”
BackgroundBoth STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
Gordziel, C., Bratsch, J., Moriggl, R., Knösel, T., & Friedrich, K. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.274 · Cited by 102 · cited 1×
“tive correlation of STAT1 expression and better prognosis [4,5].”
BackgroundMarkowitz, J., Wang, J., Vangundy, Z., You, J., Yildiz, V. O., Yu, L., Foote, I. P., Branson, O. E., Stiff, A. R., Brooks, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14970-0 · Cited by 102 · cited 1×
“Consequently, dendritic cell (DC) antigen presentation was inhibited, suggesting that STAT1 nitration mediates MDSCs’ inhibitory effects on immune cells during cancer [40].”
BackgroundSTAT1 in cancer: friend or foe?
Zhang, Y., & Liu, Z. (2017) · PubMed · Cited by 86
Karin, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.557586 · Cited by 84 · cited 1×
“In mice, MDSCs are grouped into polymorphonuclear (PMN-MDSCs) and mononuclear (M-MDSCs) subsets based on the expressions of Ly6C and Ly6G markers [17,18].”
BackgroundSTAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest
Dimco, G., Knight, R. A., Latchman, D. S., & Stephanou, A. (2010) · Cell Cycle · doi:10.4161/cc.9.23.13955 · Cited by 82 · cited 2×
“In the context of colon cancer, STAT1 is an antioncogenic molecule that acts in part through upregulating caspases [30], enhancing the expression of apoptosis-inducing ligand (TRAIL) [31] and cyclin-dependent kinase inhibitors [32], increasing phosphoinositide 3-kinase (PI3K) class IB signaling, downregulating the pro…”
BackgroundOrtiz, M. L., Kumar, V., Martner, A., Mony, S., Donthireddy, L., Condamine, T., Seykora, J., Knight, S. C., Malietzis, G., Lee, G. H., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140835 · Cited by 80 · cited 5×
“Interestingly, the increased accumulation of MDSCs in the tissues of patients with inflammation or cancer was associated with an increased risk of tumor development [19].”
BackgroundInfluentialRyan, N. M., Anderson, K., Volpedo, G., Hamza, O., Varikuti, S., Satoskar, A. R., & Oghumu, S. (2019) · International Journal of Cancer · doi:10.1002/ijc.32781 · Cited by 79 · cited 2×
“STAT1 helps to maintain effective T-cell-mediated antitumor immune responses in different types of cancers [28,29].”
BackgroundMedina‐Echeverz, J., Haile, L. A., Zhao, F., Gamrekelashvili, J., Ma, C., Métais, J., Dunbar, C. E., Kapoor, V., Manns, M. P., Korangy, F., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201444497 · Cited by 71 · cited 1×
“Furthermore, the activation of STAT1 through IFN-γR could reduce PMN-MDSCs’ survival and suppressive activity by repressing the expression of the anti-apoptotic Bcl-2-related protein A1 [41].”
BackgroundEffect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer
McDermott, U., Longley, D. B., Galligan, L., Allen, W., Wilson, T., & Johnston, P. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0961 · Cited by 66 · cited 2×
“In the context of colon cancer, STAT1 is an antioncogenic molecule that acts in part through upregulating caspases [30], enhancing the expression of apoptosis-inducing ligand (TRAIL) [31] and cyclin-dependent kinase inhibitors [32], increasing phosphoinositide 3-kinase (PI3K) class IB signaling, downregulating the pro…”
BackgroundChoi, E. A., Lei, H., Maron, D. J., Wilson, J. M., Barsoum, J., Fraker, D. L., El‐Deiry, W. S., & Spitz, F. R. (2003) · PubMed · Cited by 59
CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment
Zhang, Q.-Q., Hu, X.-W., Liu, Y.-L., Ye, Z.-J., Gui, Y.-H., Zhou, D.-L., Qi, C.-L., He, X.-D., Wang, H., & Wang, L.-J. (2015) · Scientific Reports · doi:10.1038/srep15948 · Cited by 54 · cited 1×
“CD11b+Ly6ClowLy6G+ granulocytic cells were shown to be involved in angiogenesis and tumor growth in colorectal carcinoma, and MDSCs can infiltrate the tumor environment to activate Wnt/β-catenin signaling, thus promoting tumor cell proliferation [38].”
BackgroundThe ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth
Nivarthi, H., Gordziel, C., Themanns, M., Kramer, N., Eberl, M., Rabe, B., Schlederer, M., Rose‐John, S., Knösel, T., Kenner, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9315 · Cited by 48 · cited 1×
“A reduction in STAT1 expression and/or a loss of its activation occurs in malignant colorectal cancer cells [7].”
BackgroundHuman colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses
Xie, Z.-H., Qu, Y., Leng, Y., Sun, W., Ma, S., Wei, J., Hu, J.-G., & Zhang, X. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s79431 · Cited by 43 · cited 1×
“Published data show that chronic inflammation is present in almost all the observed sporadic colorectal adenoma samples and that IL-17A is upregulated since the adenoma stage and its level remains high until the cancer stage [23,24].”
BackgroundVarikuti, S., Oghumu, S., Elbaz, M., Volpedo, G., Ahirwar, D. K., Alarcon, P. C., Sperling, R. H., Moretti, E., Pioso, M. S., Kimble, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1361088 · Cited by 41 · cited 1×
“The increased accumulation of CD11b+Ly6G+ granulocytic cells has been associated with augmented metastasis in breast cancer and head and neck squamous cell carcinoma during STAT1 deficiency [28,39].”
BackgroundDeficiency in STAT1 Signaling Predisposes Gut Inflammation and Prompts Colorectal Cancer Development
León‐Cabrera, S., Vázquez-Sandoval, A., Molina-Guzman, E., Delgado-Ramirez, Y. G., Delgado‐Buenrostro, N. L., Callejas, B. E., Chirino, Y. I., Pérez‐Plasencia, C., Rodríguez‐Sosa, M., Olguín, J. E., et al. (2018) · Cancers · doi:10.3390/cancers10090341 · Cited by 38 · cited 9×
“During the very early stages of CAC initiation, STAT1 knockout mice (STAT1-/-) presented elevated colonic epithelial cell proliferation, decreased apoptosis, and the overexpression of the antiapoptotic protein Bcl-2 in the colon [8].”
BackgroundMethodResultSelf-citationTanaka, A., Zhou, Y., Ogawa, M., Shia, J., Klimstra, D. S., Wang, J. Y., & Roehrl, M. H. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229252 · Cited by 37 · cited 1×
“Recently, a correlation has been reported between shorter patient survival times and the high protein expression of STAT1 in early stage colorectal cancer [35].”
BackgroundFlood, B., Manils, J., Nulty, C., Flis, E., Kenealy, S., Barber, G. L., Fay, J., Mills, K. H. G., Kay, E. W., & Creagh, E. M. (2018) · Oncogene · doi:10.1038/s41388-018-0613-5 · Cited by 34 · cited 2×
“In the context of colon cancer, STAT1 is an antioncogenic molecule that acts in part through upregulating caspases [30], enhancing the expression of apoptosis-inducing ligand (TRAIL) [31] and cyclin-dependent kinase inhibitors [32], increasing phosphoinositide 3-kinase (PI3K) class IB signaling, downregulating the pro…”
BackgroundCorrelation of STAT1 with Apoptosis and Cell-Cycle Markers in Esophageal Squamous Cell Carcinoma
Zhang, Y., Zhang, Y., Yun, H., Lai, R. L., & Su, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113928 · Cited by 33 · cited 1×
“This is related to the ability of STAT1 to induce the expression of members of the cell surface death receptor family and their ligands [9,10] and a number of proapoptotic and cell-cycle genes, such as caspases, BCL-2, BCL-XL, p27, and p21WAF1 [11].”
BackgroundCui, G., Yang, H., Zhao, J., Yuan, A., & Florholmen, J. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9799-1 · Cited by 31 · cited 2×
“Published data show that chronic inflammation is present in almost all the observed sporadic colorectal adenoma samples and that IL-17A is upregulated since the adenoma stage and its level remains high until the cancer stage [23,24].”
BackgroundWang, S., Darini, C., Désaubry, L., & Koromilas, A. E. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0416 · Cited by 28 · cited 2×
“In the context of colon cancer, STAT1 is an antioncogenic molecule that acts in part through upregulating caspases [30], enhancing the expression of apoptosis-inducing ligand (TRAIL) [31] and cyclin-dependent kinase inhibitors [32], increasing phosphoinositide 3-kinase (PI3K) class IB signaling, downregulating the pro…”
BackgroundZhang, Y., Wang, J., Wang, W., Tian, J., Yin, K., Tang, X., Ma, J., Xu, H., & Wang, S. (2016) · Tumor Biology · doi:10.1007/s13277-016-5414-2 · Cited by 23
Friedrich, J., Heim, L., Trufa, D. I., Sîrbu, H., Rieker, R. J., Chiriac, M. T., & Finotto, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26441 · Cited by 14 · cited 1×
“STAT1 helps to maintain effective T-cell-mediated antitumor immune responses in different types of cancers [28,29].”
BackgroundInduction of arginase-1 in MDSC requires exposure to CD3/CD28 activated T cells
Abdelaal, A. M., Bian, Z., Culpepper, C. D., & Liu, Y. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.198.supp.154.13 · Cited by 7 · cited 5×
“Scale bars: 50 µm; (D) confocal representatives merged images of the immunofluorescence staining of the distal/affected colon tissue at day 77 using an anti-iNOS antibody (green) or anti-Arginase-1 antibody (green) and DAPI (blue) counterstaining.”
BackgroundInfluential
Cited by
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota
Li, J., Ji, Y., Chen, N., Dai, L., & Deng, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01139-8 · Cited by 51
“However, abnormal STAT3 activation is also closely related to the malignant progression and pathogenesis of solid tumors such as CAC [58].”
BackgroundQian, X., Bi, Q., Wang, Z.-N., Han, F., Liu, L., Song, L., Li, C., Zhang, A., & Ji, X. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116198 · Cited by 43
Liu, W., Kuang, T., Liu, L., & Deng, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1407449 · Cited by 45
IL-17A promotes Helicobacter pylori-induced gastric carcinogenesis via interactions with IL-17RC
Kang, J. H., Park, S., Rho, J., Hong, E.-J., Cho, Y., Won, Y., & Kwon, H. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01342-5 · Cited by 33
“1 3 which can promote the initial stages of tumorigenesis [37, 38].”
Background
Metadata
- Authors
- Delgado-Ramirez, Y., Baltazar-Perez, I., Martinez, Y., Callejas, B. E., Medina-Andrade, I., Olguín, J. E., Delgado-Buenrostro, N. L., Chirino, Y. I., Terrazas, L. I., & Leon-Cabrera, S.
- Affiliations
- Universidad Nacional Autónoma de México, Facultad de Estudios Superiores Iztacala (MX)
- Unidad de Biomedicina, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Edo. De México 54090, Mexico
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-07-19
- Volume
- 22
- Issue
- 14
- Pages
- 7695
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8306338
- OpenAlex
- W3185720931
- Cited by
- 19
- References
- 52
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 3 · 2022: 4
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- CONACYT (A1S23944 and 315817)
- Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica, PAPIIT, UNAM. (IN215421 and IN226519)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- STAT1, colitis-associated colorectal cancer, IL-17, myeloid-derived suppressor cells, granulocytic MDSCs, neutrophil recruitment, tumor suppressor, STAT3, arginase-1, inducible nitric oxide synthase, chronic intestinal inflammation, tumor microenvironment, STAT1-deficient mice
- MeSH terms
- Myeloid-Derived Suppressor Cells, Colitis-Associated Neoplasms, Animals, Female, Granulocytes, Mice, Inbred BALB C, Neoplasms, Experimental, Mice, Knockout, Disease Progression, Interleukin-17, STAT1 Transcription Factor, Mice, Antibodies, Neutralizing, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.